| US 7,479,277 B2 | ||
| Method for reducing intraocular pressure using integrin-linked kinase inhibitor | ||
| Donna M. Peters, Middleton, Wis. (US); and Jennifer A. Faralli née Peterson, Madison, Wis. (US) | ||
| Assigned to Wisconsin Alumni Research Foundation, Madison, Wis. (US) | ||
| Filed on Feb. 24, 2006, as Appl. No. 11/361,243. | ||
| Claims priority of provisional application 60/655782, filed on Feb. 24, 2005. | ||
| Prior Publication US 2006/0212007 A1, Sep. 21, 2006 | ||
| Int. Cl. A61K 39/395 (2006.01); A61K 38/16 (2006.01) | ||
| U.S. Cl. 424—146.1 [514/8; 514/44; 514/81] | 2 Claims |
| 1. A method for reducing intraocular pressure elevation in an eye of a human or non-human mammalian subject having or being
susceptible to primary-open-angle-glaucoma-associated elevated intraocular pressure relative to a normal physiological intraocular
pressure, the method comprising the steps of:
administering to the eye an amount of an integrin-linked kinase (ILK) inhibitor selected from the group consisting of KP392
and QLT0267 in an amount sufficient to disrupt actin cytoskeletal organization of trabecular meshwork cells thereby reducing
the elevated intraocular pressure; and
quantifying the reduction in intraocular pressure.
|